What's new

Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 63, Status: Authorised

Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 63, Status: Authorised

Apr 3, 2025 - 15:41
 0
Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 63, Status: Authorised
Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 63, Status: Authorised
Read More

Tags:

Previous Article

FDA misses approval deadline for Novavax’s COVID-19 vaccine

Next Article

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Dat...

Related Posts

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025  0

Type-IA variations: questions and answers

Type-IA variations: questions and answers

Feb 19, 2025  0

Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Status: Opinion

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0